Handelsbanken Fonder’s Atara Biotherapeutics ATRA Stock Holding History

Handelsbanken Fonder’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-764	Closed	-$72K	–	1562
2022 Q3	$72K	Hold	764	–	–	﹤0.01%	1547
2022 Q2	$149K	Hold	764	–	–	﹤0.01%	1536
2022 Q1	$177K	Hold	764	–	–	﹤0.01%	1646
2021 Q4	$301K	Hold	764	–	–	﹤0.01%	1611
2021 Q3	$342K	Hold	764	–	–	﹤0.01%	1553
2021 Q2	$297K	Buy	764 +128	+20%	+$45.7K	﹤0.01%	1631
2021 Q1	$228K	Buy	+636	New	+$281K	﹤0.01%	1518

Other funds holding ATRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Handelsbanken Fonder's ATRA Position: Q4 2022 in Review

Handelsbanken Fonder sold out of Atara Biotherapeutics (ATRA) in Q4 2022, closing a stake of 764 shares — an estimated $72K sold.

Handelsbanken Fonder first reported a position in ATRA in Q1 2021 and held it in 7 quarters. The position peaked at $342K in Q3 2021. 139 funds tracked by Wall St. Rank hold ATRA as of Q4 2022.

Handelsbanken Fonder reported no remaining Atara Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Handelsbanken Fonder sold 764 Atara Biotherapeutics shares in Q4 2022, an estimated $72K.
Handelsbanken Fonder first reported a position in Atara Biotherapeutics in Q1 2021 and held it in 7 quarters.
Handelsbanken Fonder's Atara Biotherapeutics position peaked at $342K in Q3 2021.
139 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2022.

Based on Handelsbanken Fonder's 13F filing for Q4 2022, filed 7 Feb 2023.